Cargando…

Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease

The etiology of Parkinson’s disease (PD) is significantly influenced by disease-causing changes in the protein alpha-Synuclein (aSyn). It can trigger and promote intracellular stress and thereby impair the function of dopaminergic neurons. However, these damage mechanisms do not only extend to neuro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zella, Maria Angela Samis, Metzdorf, Judith, Ostendorf, Friederike, Maass, Fabian, Muhlack, Siegfried, Gold, Ralf, Haghikia, Aiden, Tönges, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406239/ https://www.ncbi.nlm.nih.gov/pubmed/30708997 http://dx.doi.org/10.3390/cells8020105

Ejemplares similares

Emerging Immunotherapies for Parkinson Disease
por: Zella, Samis M. A., et al.
Publicado: (2018)

Propionic Acid and Fasudil as Treatment against Rotenone Toxicity in an In Vitro Model of Parkinson’s Disease
por: Ostendorf, Friederike, et al.
Publicado: (2020)

Successful therapy with rituximab in three patients with probable neurosarcoidosis
por: Zella, Samis, et al.
Publicado: (2018)

Data-driven subtyping of Parkinson’s disease: comparison of current methodologies and application to the Bochum PNS cohort
por: Chen, Qiang, et al.
Publicado: (2023)

A Propagated Skeleton Approach to High Throughput Screening of Neurite Outgrowth for In Vitro Parkinson’s Disease Modelling
por: Schikora, Justus, et al.
Publicado: (2021)

Brainstem Raphe Alterations in TCS: A Biomarker for Depression and Apathy in Parkinson's Disease Patients
por: Richter, Daniel, et al.
Publicado: (2018)

Parkinson’s Disease Multimodal Complex Treatment (PD-MCT): Analysis of Therapeutic Effects and Predictors for Improvement
por: Hartelt, Elke, et al.
Publicado: (2020)

Antibody-based immunotherapies for Parkinsonian syndromes
por: Tönges, Lars, et al.
Publicado: (2019)

Short-chain fatty acids in the context of Parkinson’s disease
por: Metzdorf, Judith, et al.
Publicado: (2021)

Impairment of Motor Function Correlates with Neurometabolite and Brain Iron Alterations in Parkinson’s Disease
por: Pesch, Beate, et al.
Publicado: (2019)

COVID-19 outcomes in hospitalized Parkinson’s disease patients in two pandemic waves in 2020: a nationwide cross-sectional study from Germany
por: Scherbaum, Raphael, et al.
Publicado: (2022)

Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017
por: Zella, Maria Angela Samis, et al.
Publicado: (2020)

Alpha-synuclein–mediated DNA damage, STING activation, and neuroinflammation in Parkinson’s disease
por: Standaert, David G., et al.
Publicado: (2022)

Increased alpha-synuclein tear fluid levels in patients with Parkinson’s disease
por: Maass, Fabian, et al.
Publicado: (2020)

Impact of combined sodium chloride and saturated long-chain fatty acid challenge on the differentiation of T helper cells in neuroinflammation
por: Hammer, Anna, et al.
Publicado: (2017)

Alpha-synuclein mutations impair axonal regeneration in models of Parkinson's disease
por: Tönges, Lars, et al.
Publicado: (2014)

Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers
por: Richter, Daniel, et al.
Publicado: (2019)

Multiple sclerosis and nutrition: back to the future?
por: Gold, Ralf, et al.
Publicado: (2020)

Alpha-synuclein stimulation of astrocytes: Potential role for neuroinflammation and neuroprotection
por: Lee, He-Jin, et al.
Publicado: (2010)

Transmission of alpha-synuclein in Parkinson’s disease
por: Lee, Virginia M-Y
Publicado: (2013)

Alpha-synuclein spreading in Parkinson’s disease
por: Recasens, Ariadna, et al.
Publicado: (2014)

Alpha-Synuclein Aggregation in Parkinson's Disease
por: Srinivasan, E., et al.
Publicado: (2021)

Neurodegeneration and neuroinflammation are linked, but independent of alpha‐synuclein inclusions, in a seeding/spreading mouse model of Parkinson's disease
por: Garcia, Pierre, et al.
Publicado: (2022)

Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
por: Gómez-Benito, Mónica, et al.
Publicado: (2020)

Alpha-Synuclein and Cognitive Decline in Parkinson Disease
por: Fan, Tian-Sin, et al.
Publicado: (2021)

CXCL12 is involved in α-synuclein-triggered neuroinflammation of Parkinson’s disease
por: Li, Yuanyuan, et al.
Publicado: (2019)

Blood Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein
por: Barkovits, Katalin, et al.
Publicado: (2020)

Fingolimod for Irradiation-Induced Neurodegeneration
por: Metzdorf, Judith, et al.
Publicado: (2019)

Naturally Occurring Alpha-Synuclein Autoantibodies in Parkinson’s Disease: Sources of (Error) Variance in Biomarker Assays
por: Heinzel, Sebastian, et al.
Publicado: (2014)

Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease
por: Maraganore, Demetrius M.
Publicado: (2011)

Interaction between Neuromelanin and Alpha-Synuclein in Parkinson’s Disease
por: Xu, Shengli, et al.
Publicado: (2015)

Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation
por: George, Sonia, et al.
Publicado: (2015)

New Perspectives on Roles of Alpha-Synuclein in Parkinson’s Disease
por: Zhang, Guoxin, et al.
Publicado: (2018)

The Identification of Alpha-Synuclein as the First Parkinson Disease Gene
por: Nussbaum, Robert L.
Publicado: (2017)

Alpha-Synuclein Pathology and the Role of the Microbiota in Parkinson’s Disease
por: Fitzgerald, Emily, et al.
Publicado: (2019)

Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
por: Fields, Carroll Rutherford, et al.
Publicado: (2019)

Editorial: Biomarkers and Pathogenesis of Alpha-Synuclein in Parkinson's Disease
por: Li, Puyu, et al.
Publicado: (2021)

Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity
por: Benskey, Matthew J., et al.
Publicado: (2018)

Interventional Influence of the Intestinal Microbiome Through Dietary Intervention and Bowel Cleansing Might Improve Motor Symptoms in Parkinson’s Disease
por: Hegelmaier, Tobias, et al.
Publicado: (2020)

Temperature-Dependent Structural Changes of Parkinson's Alpha-Synuclein Reveal the Role of Pre-Existing Oligomers in Alpha-Synuclein Fibrillization
por: Ariesandi, Winny, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_49222abfgtvfco78eoenbca98j